Overview

• Omnicell Q3 2025 revenue grows 10% yr/yr, driven by connected devices and services

• Adjusted EPS for Q3 2025 beats analyst expectations

• Company repurchased 1.987 mln shares, repaid $175 mln convertible senior notes

Outlook

• Omnicell raises 2025 total revenue guidance to $1.177 bln - $1.187 bln

• Company expects Q4 2025 revenue between $306 mln and $316 mln

• Omnicell projects full-year 2025 non-GAAP EPS of $1.63 - $1.73

Result Drivers

• CONNECTED DEVICES - Omnicell's flagship point-of-care connected devices were a core driver of revenue growth

• TECHNICAL SERVICES - Growth in technical services offerings contributed to increased revenues

• CONSUMABLES AND SAAS - Increases in consumables and SaaS and Expert Services revenues supported revenue growth

Key Details

Analyst Coverage

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 5 "strong buy" or "buy", 3 "hold" and no "sell" or "strong sell"

• The average consensus recommendation for the advanced medical equipment & technology peer group is "buy"

• Wall Street's median 12-month price target for Omnicell Inc is $41.00, about 27.9% above its October 29 closing price of $29.57

• The stock recently traded at 18 times the next 12-month earnings vs. a P/E of 21 three months ago

Press Release: ID:nBw4ztyb0a

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)